Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 11;42(6):1130–1136. doi: 10.1007/s10875-022-01283-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — The emergence of neutralizing antibodies against wild-type and Omicron variants of SARS-CoV-2 in commercial immunoglobulin products. A Anti-SARS-CoV-2 spike protein antibody concentration and neutralizing capacity in consecutive batches of commercial immunoglobulin products used in clinical practice at the Immunodeficiency Unit at Karolinska University Hospital in relation to production date. The size of the dots represents the highest dilution (titer) at which the individual batch is effective in a microneutralization assay using wild-type/Wuhan strain live SARS-CoV-2. The producers are represented by different colors. In pre-pandemic batches (left of vertical line) no antibody concentration above 5.8 U/ml was observed, which is represented by a dashed horizontal line. Concentrations and titers have been adjusted to compensate for differences in total IgG concentration (100–200 g/l) in the included products. B The two immunoglobulin batches with the highest concentration of antibodies and neutralizing capacity against wild-type SARS-CoV-2 were also tested for cross-reactive neutralization capacity against the Omicron variant of SARS-CoV-2